[^1]
| RAG1 Protein |
|---|
| Gene | [RAG1](/genes/rag1) (Recombination Activating 1) |
| UniProt ID | [P15919](https://www.uniprot.org/uniprot/P15919) |
| PDB Structures | 1RMB, 1RMD, 2V27 |
| Molecular Weight | ~ 270 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | RAG1/2 recombinase complex |
is a protein encoded by the RAG1 gene that rag1 is essential for v(d)j recombination, the process that generates diverse t-cell receptor (tcr) and b-cell receptor (bcr) proteins during lymphocyte development. in the nervous system:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
The RAG1 protein is a large 270 kDa protein that forms a complex with RAG2 to mediate V(D)J recombination. The protein contains:
- Nonamer-binding domain (NBD) - Recognizes the conserved nonamer sequence (CACGTGGA) of recombination signal sequences (RSS)
- Central domain - Contains catalytic site with DDE motif (Asp587, Asp990, Glu1320)
- C-terminal regulatory region - Contains the RING finger domain with E3 ubiquitin ligase activity
The RAG1/2 complex functions as a site-specific endonuclease that introduces double-strand breaks at the border between coding and signal segments.
RAG1 is essential for V(D)J recombination, the process that generates diverse T-cell receptor (TCR) and B-cell receptor (BCR) proteins during lymphocyte development. In the nervous system:
- Neurogenesis: RAG1 expression has been detected in neural progenitor cells during development
- DNA repair: The RAG proteins can induce DNA damage and are involved in repair pathways
- Chromatin remodeling: RAG1 interacts with chromatin remodeling complexes
While primarily studied in immune cells, RAG1 has been implicated in neurodegeneration:
- RAG1-mediated DNA damage responses may be activated in AD brains
- The RAG1/RAG2 complex can generate genomic instability
- Aberrant RAG1 expression in neurons may contribute to tau pathology
- DNA damage accumulation in dopaminergic neurons may involve RAG1 activity
- RAG1-induced cell cycle re-entry could contribute to neuronal death
- RAG1 expression changes observed in motor neuron disease models
- Genomic instability from aberrant recombination may contribute to pathogenesis
Current therapeutic approaches targeting RAG1:
- RAG1 inhibitors: Small molecules targeting the catalytic site are in development for autoimmune diseases
- Gene therapy: RAG1 deficiency is treated with hematopoietic stem cell gene therapy
- DNA damage modulators: PARP inhibitors may mitigate RAG1-induced DNA damage